Literature DB >> 25904543

Synthesis and antitumor mechanisms of a copper(II) complex of anthracene-9-imidazoline hydrazone (9-AIH).

Qi-Pin Qin1, Yan-Cheng Liu, Hai-Lu Wang, Jiao-Lan Qin, Feng-Jie Cheng, Shang-Feng Tang, Hong Liang.   

Abstract

A new anthracycline derivative, anthracene-9-imidazoline hydrazone (9-AIH), was synthesized and selected as an antitumor ligand to afford a copper(II) complex of 9-AIH, cis-[Cu(II)Cl2(9-AIH)] (1). Complex 1 was structurally characterized by IR, elemental analysis, ESI-MS and single crystal X-ray diffraction analysis. By MTT assay, it was revealed that 1 showed overall a higher in vitro cytotoxicity than 9-AIH towards a panel of human tumour cell lines, with IC50 values from 0.94–3.68 μM, in which the BEL-7404 cell line was the most sensitive to 1. By spectral analyses and gel electrophoresis, the DNA binding affinity of 9-AIH and 1 was determined. 9-AIH was suggested to bind with DNA in an intercalative mode, with a quenching constant of 1.04 × 10(4) M(−1) on the EB–DNA complex. While for 1, both intercalative and covalent binding modes were suggested. By flow cytometry, 1 was found to block the cell cycle of BEL-7404 cells in a dose-dependent mode, in which it induced the G2/M phase arrest at 0.5 μM and induced the S phase arrest at higher concentrations of 1.0 or 2.0 μM. From the cellular morphological observations under different fluorescence probe staining, a dose-dependent manner of 1 to induce cell apoptosis in the late stage was suggested. Comparatively, equivalent apoptotic cells, respectively, in the early and late stages were found when incubated with 2.0 μM of 9-AIH. The mitochondrial membrane potential measured by JC-1 staining and the ROS generation in cells detected using a DCFH-DA probe suggested that the cell apoptosis induced by 1 might undergo the ROS-related mitochondrial pathway. Accordingly, the mutant p53 expression was found to be suppressed and the caspase cascade (caspase-9/3) was consequently activated by 1. This action mechanism for 1 in the BEL-7404 cells was unique and was not found in the presence of 9-AIH under the same conditions, indicating their different antitumor mechanism. Furthermore, the in vivo acute toxicity of 1 tested on mice indicated that 1 should be a high cytotoxic antitumor agent, with the LD50 value in the range of 32–45 mg kg(−1), which is much higher than that of 9-AIH. From the above results, the central Cu(II) of 1 in the coordinated mode with 9-AIH was believed to play a key role in exerting both the high cytotoxicity and the effective antitumor mechanism.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25904543     DOI: 10.1039/c5mt00027k

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  9 in total

1.  A vanillin-based copper(ii) metal complex with a DNA-mediated apoptotic activity.

Authors:  Wendy M T Q de Medeiros; Mayara J C de Medeiros; Edinilton M Carvalho; Jailma A de Lima; Verônica da S Oliveira; Ana C F de B Pontes; Francisco O N da Silva; Javier A Ellena; Hugo A de O Rocha; Eduardo H S de Sousa; Daniel de L Pontes
Journal:  RSC Adv       Date:  2018-05-10       Impact factor: 4.036

2.  Ternary copper(II) complex: NCI60 screening, toxicity studies, and evaluation of efficacy in xenograft models of nasopharyngeal carcinoma.

Authors:  Munirah Ahmad; Shazlan-Noor Suhaimi; Tai-Lin Chu; Norazlin Abdul Aziz; Noor-Kaslina Mohd Kornain; D S Samiulla; Kwok-Wai Lo; Chew-Hee Ng; Alan Soo-Beng Khoo
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

3.  Ubidecarenone-Loaded Nanostructured Lipid Carrier (UB-NLC): Percutaneous Penetration and Protective Effects Against Hydrogen Peroxide-Induced Oxidative Stress on HaCaT Cells.

Authors:  Jianmin Wang; Huiyun Wang; Qiang Xia
Journal:  Int J Mol Sci       Date:  2018-06-25       Impact factor: 5.923

4.  Facile total synthesis of lysicamine and the anticancer activities of the RuII, RhIII, MnII and ZnII complexes of lysicamine.

Authors:  Jiao-Lan Qin; Ting Meng; Zhen-Feng Chen; Xiao-Li Xie; Qi-Pin Qin; Xiao-Ju He; Ke-Bin Huang; Hong Liang
Journal:  Oncotarget       Date:  2017-07-26

5.  Syntheses and Biological Studies of Cu(II) Complexes Bearing Bis(pyrazol-1-yl)- and Bis(triazol-1-yl)-acetato Heteroscorpionate Ligands.

Authors:  Maura Pellei; Valentina Gandin; Luciano Marchiò; Cristina Marzano; Luca Bagnarelli; Carlo Santini
Journal:  Molecules       Date:  2019-05-07       Impact factor: 4.411

6.  Synthesis and Cytotoxic Activity Evaluation of New Cu(I) Complexes of Bis(pyrazol-1-yl) Acetate Ligands Functionalized with an NMDA Receptor Antagonist.

Authors:  Maura Pellei; Luca Bagnarelli; Lorenzo Luciani; Fabio Del Bello; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia; Michele De Franco; Valentina Gandin; Cristina Marzano; Carlo Santini
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923

7.  Cu(I) and Cu(II) Complexes Based on Lonidamine-Conjugated Ligands Designed to Promote Synergistic Antitumor Effects.

Authors:  Fabio Del Bello; Maura Pellei; Luca Bagnarelli; Carlo Santini; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia; Chiara Battocchio; Giovanna Iucci; Irene Schiesaro; Carlo Meneghini; Iole Venditti; Nitya Ramanan; Michele De Franco; Paolo Sgarbossa; Cristina Marzano; Valentina Gandin
Journal:  Inorg Chem       Date:  2022-03-14       Impact factor: 5.165

8.  Controlling of Photophysical Behavior of Rhenium(I) Complexes with 2,6-Di(thiazol-2-yl)pyridine-Based Ligands by Pendant π-Conjugated Aryl Groups.

Authors:  Anna M Maroń; Joanna Palion-Gazda; Agata Szłapa-Kula; Ewa Schab-Balcerzak; Mariola Siwy; Karolina Sulowska; Sebastian Maćkowski; Barbara Machura
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

9.  Oxoaporphine Metal Complexes (CoII, NiII, ZnII) with High Antitumor Activity by Inducing Mitochondria-Mediated Apoptosis and S-phase Arrest in HepG2.

Authors:  Jiao-Lan Qin; Wen-Ying Shen; Zhen-Feng Chen; Li-Fang Zhao; Qi-Pin Qin; Yan-Cheng Yu; Hong Liang
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.